ROTHBLATT MARTINE A sold $5.2M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $551.13 ($548.16–$555.76, $5.24M total) across 8 trades on 2026-07-09 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO/Chairperson sold $5.24M of shares across eight trades at $548.1570 to $555.7633, with holdings after the sale at 40,513 shares.
Market read
Provides a fresh, timestamped insider selling datapoint, but the 10b5-1 structure suggests limited incremental fundamental information.
What to watch
Traders may over-weight insider sales; without accompanying guidance, trial, or regulatory updates, the signal is typically weak.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics.
Ticker impact
United Therapeutics Form 4 shows CEO and Chairperson Rothblatt sold 9,500 shares on 2026-07-09 under a 10b5-1 plan.
Likely limited near-term impact; any reaction should fade unless accompanied by other company-specific news.
The filing is primary-source and time-stamped, but the presence of a pre-arranged 10b5-1 plan reduces the likelihood of it reflecting new negative information.
Market effects
No direct sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider sale disclosure.
- insiderMartine A. Rothblatt
CEO and Chairperson who executed the open-market sale under a 10b5-1 plan.
